EXPAND-EV · EXPANDing the value of Extracellular Vesicles as carriers of biomarker and therapy in precision healthcare

Линиите свързват координатора с партньорите.

Накратко на български

Цел на проекта

Extracellular vesicles (EVs) have been identified as important signaling mediators in a myriad of physiological and pathological processes. There is an emerging effort to advance the exploitation of EVs in precision healthcare, with special emphasis on drug delivery and liquid biopsy. However, the current technology readiness level in the field and lack of standardized methodology guidelines are limiting the exploitation of EVs, so a significant leap toward the establishment of novel tools has to be made. EXPAND-EV’s main goal is to provide a unique solution for advancing the current diagnostic and therapeutic potential of EVs by developing and implementing versatile, scalable, cost-effective and reproducible purification systems, based on single-domain antibody affinity technology for high-performance scalable EVs capture, in two parallel lines of research: (I)the system will be validated in clinical laboratory settings on breast (BC), liver (HC) and lung cancer (LC) by analyzing differential expression of multi -omics (proteomic, glycomic and transcriptomic) EVs-related features, with the goal to develop a panel of biomarkers that would contribute in timely diagnostics, enable a convenient and non-invasive prognosis assessment and tailored therapy. (II)development of GMP-compliant protocol for producing edible plant EVs as carriers of therapeutic siRNA molecules. Their safety profile and therapeutic potential will be tested on BC, HC and LC cell lines and mouse models. By establishing a consortium composed of excellent research groups and SMEs across Europe, EXPAND-EV will bring forth the needed paradigm shift in EVs research by solving the major bottleneck issue in the field. Creating a simple, robust, cheap, scalable and reproducible EVs purification system will provide much-needed technology for application of EVs in personalized medicine, leading the transition of EVs use from a promising laboratory concept to a feasible and applicable theranostic agent.

Оригинален текст от CORDIS (на английски).

Участници

• HEMIJSKI FAKULTET, UNIVERZITET U BEOGRADU · BeogradКоординаторСърбия
• ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON · ATHINAГърция
• EXELIXIS DIACHEIRISI EREVNAS KAI EPIKOINONIA EE · GERAKAS ATTIKIГърция
• FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA · BARCELONAИспания
• GENOS DOO ZA VJESTACENJE I ANALIZU · OSIJEKХърватия
• HELLENIC PASTEUR INSTITUTE · AthensГърция
• INSTITUT ZA ONKOLOGIJU I RADIOLOGIJU SRBIJE · BelgradeСърбия
• INSTITUTE OF CHEMISTRY, TECHNOLOGY AND METALLURGY · BelgradeСърбия
• Innovative Centre Faculty of Chemistry Belgrade LTD · BelgradeСърбия
• RHEINISCH-WESTFAELISCHE TECHNISCHE HOCHSCHULE AACHEN · AachenГермания
• SITOOLS BIOTECH GMBH · PlaneggГермания
• THERACELL LABORATORIES PRIVATE EQUITY COMPANY · KOROPIГърция
• UNIVERZA V NOVI GORICI · Nova GoricaСловения

Връзки

• Виж в CORDIS
• DOI: 10.3030/101182851
• https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e524250513&appId=PPGMS